Sandelowsky Hanna, Ställberg Björn, Wiklund Fredrik, Telg Gunilla, de Fine Licht Sofie, Janson Christer
Karolinska Institutet, Department of Medicine, Division of Clinical Epidemiology, Solna, Sweden.
Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Solna, Sweden.
J Asthma Allergy. 2022 Apr 13;15:475-486. doi: 10.2147/JAA.S357086. eCollection 2022.
Symptom control has not improved in Swedish asthma patients during the last two decades. Guidelines recommend annual reviews for asthma patients treated with maintenance inhaled corticosteroids (ICS). We aimed to describe how visit patterns in an ICS-treated asthma population in Sweden were related to applicable asthma guidelines.
Swedish electronic health data for incident asthma patients, ≥18 years, with at least one ICS collection (index date) between 2006 and 2017 were included. Exacerbations were defined as hospitalizations, emergency visits, or collection of oral corticosteroids (OCS). Probability of an asthma-related regular follow-up visit and probability of a follow-up visit after an exacerbation, both within 15 months, were estimated using the cumulative incidence function, time-to-event analysis, and incident rate ratios.
In 51,349 asthma patients (mean age 47.6 years, 63% females), 17,573 had a regular asthma visit in primary or secondary care within 15 months after the index, yielding an overall probability of a visit of 37.4%. Patients with a follow-up visit had higher ICS collection and lower OCS collection than patients without regular visits. Among 22,097 patients with acute exacerbations, the probability of a visit within 15 months after an exacerbation was 31.0%. The probability of having a visit increased during the study period.
Only one-third of ICS-treated asthma patients, regardless of asthma severity, had a regular or post-exacerbation follow-up visit within a 15-month period. The consequences of this lack of adherence to guidelines need further evaluation to secure optimal asthma management.
在过去二十年中,瑞典哮喘患者的症状控制并未得到改善。指南建议对接受维持性吸入糖皮质激素(ICS)治疗的哮喘患者进行年度复查。我们旨在描述瑞典接受ICS治疗的哮喘人群的就诊模式与适用的哮喘指南之间的关系。
纳入2006年至2017年间年龄≥18岁、有至少一次ICS处方(索引日期)的瑞典哮喘患者的电子健康数据。加重发作定义为住院、急诊就诊或口服糖皮质激素(OCS)处方。使用累积发病率函数、事件发生时间分析和发病率比,估计在15个月内进行哮喘相关定期随访就诊的概率以及加重发作后进行随访就诊的概率。
在51349例哮喘患者(平均年龄47.6岁,63%为女性)中,17573例在索引日期后的15个月内在初级或二级医疗机构进行了定期哮喘就诊,总体就诊概率为37.4%。与未进行定期就诊的患者相比,进行随访就诊的患者ICS处方量更高,OCS处方量更低。在22097例急性加重发作的患者中,加重发作后15个月内就诊的概率为31.0%。在研究期间,就诊概率有所增加。
无论哮喘严重程度如何,在15个月内,只有三分之一接受ICS治疗的哮喘患者进行了定期或加重发作后的随访就诊。这种不遵守指南的后果需要进一步评估,以确保实现最佳的哮喘管理。